

Please add new claims 73 and 74 to read as follows:

73. (New) A recombinant vector comprising a polynucleotide according to any one of claims 64-66.

74. (New) A host cell comprising a recombinant vector according to claim 73.

REMARKS

Applicants wish to thank Examiner Souaya for the productive telephonic interview conducted on February 25, 2003. Favorable reconsideration of the subject application is respectfully requested in view of the above amendments and following remarks. Claims 64-72 are currently under examination in the subject application. By the above amendment, claims 67-71 have been cancelled and new claims 73 and 74, drawn to recombinant vectors and host cells comprising the claimed polynucleotides, have been added. It is urged that support for the above amendments can be found throughout the specification as originally filed and that none of the amendments constitutes new matter. More specifically, support for recombinant vectors and host cells can be found, for example, at page 3, lines 21-24, page 33, lines 8-9, and elsewhere throughout the specification as originally filed. Moreover, it is noted that vectors and host cells comprising the claimed polynucleotides constitute Group I subject matter originally elected by Applicants in reply to the Restriction Requirement mailed December 19, 2001. The above amendments are not to be construed as acquiescence with regard to the Examiner's rejections, and are made without prejudice to prosecution of any subject matter modified and/or removed by this amendment in a related divisional, continuation and/or continuation-in-part application.

Rejection Under 35 U.S.C. § 112, First Paragraph (enablement)

Claims 65-72 stand rejected under 35 U.S.C. § 112, first paragraph, on the basis that the specification allegedly does not enable any person skilled in the art to make or use the invention commensurate in scope with the current claims.

Applicants respectfully traverse this rejection. As discussed with Examiner Souaya during the telephonic interview conducted February 25, 2003, the skilled artisan, in view of the instant specification, would indeed understand how to make and use isolated polynucleotides commensurate with the scope of the invention claimed. More particularly, upon accepting that SEQ ID NO: 107 represents an isolated polynucleotide having a prostate cancer-